115
Participants
Start Date
June 26, 2019
Primary Completion Date
March 7, 2024
Study Completion Date
March 7, 2024
ZEN003694
PO QD
Talazoparib
PO QD
Institut Jules Bordet, Anderlecht
UZ Leuven, Leuven
Memorial Sloan Kettering Cancer Center, New York
University of Pennsylvania, Philadelphia
START Madrid, Madrid
Emory University Winship Cancer Institute, Atlanta
Tennessee Oncology (Sarah Cannon), Nashville
University of Kansas Cancer Center, Westwood
MD Anderson, Houston
Banner MD Anderson Cancer Center, Gilbert
The First Affiliated Hosptial of Bengbu Medical College, Bengbu
Affliated Hospital of Jining Medical University, Jining
Tianjing Medical University Cancer Institute & Hospital, Tianjin
Hunan Cancer Hospital, Changsha
Sun Yat-sen University Cancer Center, Guangzhou
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
The Second People's Hospital of Neijiang, Neijiang
Dana Farber Cancer Institute, Boston
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
Lead Sponsor
Collaborators (1)
Pfizer
INDUSTRY
Newsoara Biopharma Co., Ltd.
INDUSTRY
Zenith Epigenetics
INDUSTRY